DOI: 10.1023/a:1010682916808. Progress in the Development of Alternative Pharmaceutical Formulations of Taxanes

Progress in the Development of Alternative Pharmaceutical Formulations of Taxanes

10.1023/a:1010682916808

Crossref journal-article

Springer Science and Business Media LLC

Investigational New Drugs (297)

Bibliography

Nuijen, B., Bouma, M., Schellens, J. H. M., & Beijnen, J. H. (2001). Progress in the Development of Alternative Pharmaceutical Formulations of Taxanes. Investigational New Drugs, 19(2), 143â153.

Authors 4

Bastiaan Nuijen (first)
Marjan Bouma (additional)
Jan H.M. Schellens (additional)
Jos H. Beijnen (additional)

References 55 Referenced 78

Huizing MT, Sewberath Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CHN, Vermorken JB, Beijnen JH: Taxanes: a new class of antitumor agents. Cancer Inv 13: 381–404, 1995 (10.3109/07357909509031919) / Cancer Inv by MT Huizing (1995)
Straubinger RM: Biopharmaceutics of paclitaxel (Taxol): formulation, activity, and pharmacokinetics. In: Suffness M (ed) Taxolr: Science and Applications. CRC press, 1996, pp 237–258 (10.1201/9780138737361-12)
Adams JD, Flora KP, Goldspiel BR, Wilson JW, Arbuck SG, Finley R: Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst 15: 141–147, 1993 / J Natl Cancer Inst by JD Adams (1993)
Meerum Terwogt JM, Nuijen B, Ten Bokkel Huinink WW, Beijnen JH: Alternative formulations of paclitaxel. Canc Treat Rev 23: 87–95, 1997 (10.1016/S0305-7372(97)90022-0) / Canc Treat Rev by JM Meerum Terwogt (1997)
Nannan Panday VR, Huizing MT, ten Bokkel Huinink WW, Vermorken JB, Beijnen JH: Hypersensitivity reactions to the taxanes paclitaxel and docetaxel. Clin Drug Invest 14: 418–427, 1997 (10.2165/00044011-199714050-00011) / Clin Drug Invest by VR Nannan Panday (1997)
Lorenz W, Reimann HJ, Schmal A, Dormann P, Schwarz B, Neugebauer E, Doenicke A: Histamine release in dogs by Cremophor ELr and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 7: 63–67, 1977 (10.1007/BF01964882) / Agents Actions by W Lorenz (1977)
Wilson DB, Beck TM, Gundlach CA: Paclitaxel formulation as a cause of ethanol intoxication. Ann Pharmacother 31: 873–875, 1997 (10.1177/106002809703100714) / Ann Pharmacother by DB Wilson (1997)
Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JHM: Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Canc Res 56: 2112–2115, 1996 / Canc Res by A Sparreboom (1996)
van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH: Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 81: 330–335, 1999 (10.1038/sj.bjc.6690696) / Br J Cancer by O van Tellingen (1999)
Liebmann J, Cook J, Lipschultz C: The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines. Cancer Chemother Pharmacol 33: 331–339, 1994 (10.1007/BF00685909) / Cancer Chemother Pharmacol by J Liebmann (1994)
Trissel LA: Pharmaceutical properties of paclitaxel and their effects on preparation and administration. Pharmacotherapy 17: 133S–139S, 1997 (10.1002/j.1875-9114.1997.tb03815.x) / Pharmacotherapy by LA Trissel (1997)
Jonkman-de Vries JD, Flora KP, Bult A, Beijnen JH: Pharmaceutical development of (investigational) anticancer agents for parenteral use – a review. Drug Develop Indust Pharm 22: 475–494, 1996 (10.3109/03639049609108353) / Drug Develop Indust Pharm by JD Jonkman-de Vries (1996)
Sweetana S, Akers MJ: Solubility principles and practices for parenteral drug dosage form development. PDA J Pharm Sci Technol 50: 330–342, 1996 / PDA J Pharm Sci Technol by S Sweetana (1996)
Product information Taxol (Bristol-Myers Squibb, Princeton, US)
Ramaswamy M, Zhang X, Burt HM, Wasan KM: Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers. J Pharm Sci 86: 460–464, 1997 (10.1021/js960333n) / J Pharm Sci by M Ramaswamy (1997)
Zhang X, Burt HM, Von Hoff D, Dexter D, Mangold G, Degen D, Oktaba AM, Hunter WL: An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel. Cancer Chemother Pharmacol 40: 81–86, 1997 (10.1007/s002800050630) / Cancer Chemother Pharmacol by X Zhang (1997)
Zhang X, Burt HM, Mangold G, Dexter D, Von Hoff D, Mayer L, Hunter WL: Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel. Anticancer Drugs 8: 696–701, 1997 (10.1097/00001813-199708000-00008) / Anticancer Drugs by X Zhang (1997)
Product information Taxotere (Rhône-Poulenc Rorer)
Tarr BD, Sambandan TG, Yalkowsky SH: A new parenteral emulsion for the administration of Taxol. Pharm Res 4: 162–165, 1987 (10.1023/A:1016483406511) / Pharm Res by BD Tarr (1987)
Simamora P, Dannenfelser RM, Tabibi SE, Yalkowski SH: Emulsion formulations for intavenous administration of paclitaxel. PDA J Pharm Sci Technol 52: 170–172, 1998 / PDA J Pharm Sci Technol by P Simamora (1998)
Lundberg BB: A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol). J Pharm Pharmacol 49: 16–21, 1997 (10.1111/j.2042-7158.1997.tb06744.x) / J Pharm Pharmacol by BB Lundberg (1997)
Kan P, Chen ZB, Lee CJ, Chu IM: Development of nonionic surfactant/phospholipid o/w emulsion as a paclitaxel delivery system. J Controlled Release 58: 271–278, 1999 (10.1016/S0168-3659(98)00164-3) / J Controlled Release by P Kan (1999)
Bartoli MH, Boitard M, Fessi H, Beriel H, Devissaguet JP, Picot F, Puisieux F: In vitro and in vivo antitumoral activity of free, and encapsulated taxol. J Microencapsulation 7: 191–197, 1990 (10.3109/02652049009021832) / J Microencapsulation by MH Bartoli (1990)
Sharma D, Chelvi TP, Chakravorty K, De TK, Maitra A, Ralhan R: Novel Taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated Taxol for drug delivery in cancer therapy. Oncol Res 8: 281–286, 1996 / Oncol Res by D Sharma (1996)
Dordunoo SK, Jackson JK, Arsenault LA: Taxol encapsulation in poly(—-caprolactone) microspheres. Cancer Chemother Pharmacol 36: 279–282, 1995 (10.1007/BF00689043) / Cancer Chemother Pharmacol by SK Dordunoo (1995)
Burt HM, Jackson JK, Bains SK, Liggins RT, Oktaba AM, Arsenault AL, Hunter WL. Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (d,l-lactic acid). Cancer Lett 88: 73–79, 1995 (10.1016/0304-3835(94)03614-O) / Cancer Lett by HM Burt (1995)
Harper E, Dang W, Lapidus RG, Garver RI: Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER Delivery System) for local-regional therapy of lung cancer tumor nodules in mice. Clin Canc Res 5: 4242–4248, 1999 / Clin Canc Res by E Harper (1999)
Alkan-Onyuksel H, Ramakrishnan S, Chai HB, Pezzuto JM: A mixed micellar formulation suitable for the parenteral administration of Taxol. Pharm Res 11: 206–212 (10.1023/A:1018943021705)
Straubinger RM, Sharma A, Murray M, Mayhew E: Novel Taxol formulations: Taxol containing liposomes. J Natl Cancer Inst Mon 15: 69–78, 1993 / J Natl Cancer Inst Mon by RM Straubinger (1993)
Sharma A, Straubinger RM: Novel Taxol formulations: preparation and characterization of Taxol-containing liposomes. Pharm Res 11: 889–896, 1994 (10.1023/A:1018994111594) / Pharm Res by A Sharma (1994)
Sharma A, Mayhew E, Bolcsak L, Cavanaugh C, Harmon P, Janoff A, Bernacki RJ: Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int J Canc 71: 103–107, 1997 (10.1002/(SICI)1097-0215(19970328)71:1<103::AID-IJC17>3.0.CO;2-J) / Int J Canc by A Sharma (1997)
Bekers O, Uijtendaal EV, Beijnen JH, Bult A, Underberg WJM: Cyclodextrins in the pharmaceutical field. Drug Dev Ind Pharm 17: 1503–1549, 1991 (10.3109/03639049109026630) / Drug Dev Ind Pharm by O Bekers (1991)
Loftsson T, Brewster ME: Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. Pharm Sci 85: 1017–1025, 1996 (10.1021/js950534b) / Pharm Sci by T Loftsson (1996)
Sharma US, Balasubramanian SV, Straubinger RM: Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrines. J Pharm Sci 84: 1223–1230, 1995 (10.1002/jps.2600841015) / J Pharm Sci by US Sharma (1995)
Mellado W, Magri NF, Kingston DGI, Garcia-Arenas R, Orr GA, Horwitz SB: Preparation and biological activity of taxol acetates. Biochem Biophys Res Com 124: 329–336, 1984 (10.1016/0006-291X(84)91557-2) / Biochem Biophys Res Com by W Mellado (1984)
Vyas DM, Wong H, Crosswell AR, Casazza AM, Knipe JO, Mamber SW, Doyle TW: Synthesis and antitumor evaluation of water soluble taxol phosphates. Bioorganic Med Chem Lett 3: 1357–1360, 1993 (10.1016/S0960-894X(00)80348-0) / Bioorganic Med Chem Lett by DM Vyas (1993)
Vyas DM: Paclitaxel (Taxolr) formulation and prodrugs. In: Farina V (ed) The Chemistry and Pharmacology of Taxol and its Derivatives, 103–130, 1995 (10.1016/S0165-7208(06)80017-6)
Ueda Y, Mikkilineni AB, Knipe JO, Rose WC, Casazza AM, Vyas DM: Novel water soluble phosphate prodrugs of Taxolr possessing in vivo antitumor activity. Bioorganic Med Chem Lett 3: 1761–1766, 1993 (10.1016/S0960-894X(00)80058-X) / Bioorganic Med Chem Lett by Y Ueda (1993)
Ueda Y, Wong H, Matiskella JD, Mikkelineni AB, Farina V, Fairchild C, Rose WC, Mamber SW, Long BH, Kerns EH, Casazza AM, Vyas DM: Synthesis and antitumor evaluation of 20-oxycarbonylpaclitaxels (paclitaxel-20-carbonates). Bioorganic Med Chem Lett 4: 1861–1864, 1994 (10.1016/S0960-894X(01)80385-1) / Bioorganic Med Chem Lett by Y Ueda (1994)
Mathew AE, Mejillano MR, Nath JP, Himes RH, Stella VJ: Synthesis and evaluation of some water-soluble prodrugs and derivatives of Taxol with antitumor activity. J Med Chem 35: 145–151, 1992 (10.1021/jm00079a019) / J Med Chem by AE Mathew (1992)
Paradis R, Pagé M: New active paclitaxel amino acids derivatives with improved water solubility. Anticancer Res 18: 2711–2716, 1998 / Anticancer Res by R Paradis (1998)
Nicolaou KC, Riemer C, Kerr MA, Rideout D, Wrasidlo W: Design, synthesis and biological activity of protaxols. Nature 364: 464–466, 1993 (10.1038/364464a0) / Nature by KC Nicolaou (1993)
Greenwald RB, Pendri A, Bolikal D, Gilbert CW: Highly water-soluble taxol derivatives: 20-polyethyleneglycol esters as potential prodrugs. Biorganic Med Chem Lett 4: 2465–2470, 1994 (10.1016/S0960-894X(01)80411-X) / Biorganic Med Chem Lett by RB Greenwald (1994)
Greenwald RB, Gilbert CW, Pendri A, Conover CD, Xia J, Martinez A: Drug delivery systems: water soluble Taxol 20-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J Med Chem 39: 424–431, 1996 (10.1021/jm950475e) / J Med Chem by RB Greenwald (1996)
Li C, Yu D, Inoue T, Yang DJ, Milas L, Hunter NR, Kim EE, Wallace S: Synthesis and evaluation of water-soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug. Anticancer Drugs 7: 642–648, 1996 (10.1097/00001813-199608000-00004) / Anticancer Drugs by C Li (1996)
Pendri A, Conover CD, Greenwald RB: Antitumor activity of paclitaxel-20-glycinate conjugated to poly(ethylene glycol): a water soluble prodrug. Anticancer Drug Des 13: 387–395, 1998 / Anticancer Drug Des by A Pendri (1998)
Dosio F, Brusa P, Crosasso, P, Arpicco S, Cattel L: Preparation and characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate. J Control Rel 47: 293–304, 1997 (10.1016/S0168-3659(97)01656-8) / J Control Rel by F Dosio (1997)
Presenti E, Franzetti C, Biasoli G: Synthesis and biological activity of water soluble polymer-bound taxol derivatives. Proc Am Ass Cancer Res 36: 307, 1995 / Proc Am Ass Cancer Res by E Presenti (1995)
Ojima I, Park YH, Sun CM, Fenoglio I, Appendino G, Pera P, Bernacki RJ: Structure-activity relationships of new taxoids derived from 14—-hydroxy-10-deacetylbaccatin III. J Med Chem 37: 1408–1410, 1994 (10.1021/jm00036a004) / J Med Chem by I Ojima (1994)
Ali SM, Hoemann MZ, Aubé J, Mitscher LA, Georg GI: Novel cytotoxic 30-(tert-butyl) 30-diphenyl analogs of paclitaxel and docetaxel. J Med Chem 38: 3821–3828, 1995 (10.1021/jm00019a012) / J Med Chem by SM Ali (1995)
Alder JD, Jarvis KP, Marsh KC, Klein LL, Clement JJ: Preclinical in vivo efficacy of two 9-dihydrotaxane analogues against human and murine tumors. Br J Cancer 73: 560–564, 1996 (10.1038/bjc.1996.98) / Br J Cancer by JD Alder (1996)
Merisko-Liversidge E, Sarpotdar P, Bruno J, Hajj S, Wei L, Peltier N, Rake J, Shaw JM, Pugh S, Polin L, Jones J, Corbett T, Cooper E, Liversidge GG: Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble drugs. Pharm Res 13: 272–278, 1996 (10.1023/A:1016051316815) / Pharm Res by E Merisko-Liversidge (1996)
Winternitz CI, Jackson JK, Oktaba AM, Burt HM: Development of a polymeric surgical paste formulation for taxol. Pharm Res 13: 368–375, 1996 (10.1023/A:1016032207246) / Pharm Res by CI Winternitz (1996)
Smith J, Stock E, Orenberg EK, Yu NY, Kanekal S, Brown DM: Intratumoral chemotherapy with sustained-release drug delivery system inhibits growth of human pancreatic cancer xenografts. Anticancer Drugs 6: 717–726, 1995 (10.1097/00001813-199512000-00002) / Anticancer Drugs by J Smith (1995)
Meerum Terwogt JM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Schellens JHM: Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet 352: 285, 1998 (10.1016/S0140-6736(98)24030-X) / Lancet by JM Meerum Terwogt (1998)

Dates

Type	When
Created	22 years, 8 months ago (Dec. 22, 2002, 5:31 p.m.)
Deposited	1 month ago (July 29, 2025, 4:01 p.m.)
Indexed	1 month ago (Aug. 2, 2025, 3:15 p.m.)
Issued	24 years, 4 months ago (May 1, 2001)
Published	24 years, 4 months ago (May 1, 2001)
Published Print	24 years, 4 months ago (May 1, 2001)

Funders 0

None

BibTeX

@article{Nuijen_2001, title={Progress in the Development of Alternative Pharmaceutical Formulations of Taxanes}, volume={19}, ISSN={1573-0646}, url={http://dx.doi.org/10.1023/a:1010682916808}, DOI={10.1023/a:1010682916808}, number={2}, journal={Investigational New Drugs}, publisher={Springer Science and Business Media LLC}, author={Nuijen, Bastiaan and Bouma, Marjan and Schellens, Jan H.M. and Beijnen, Jos H.}, year={2001}, month=may, pages={143–153} }

JSON

{
  "indexed": {
    "date-parts": [
      [
        2025,
        8,
        2
      ]
    ],
    "date-time": "2025-08-02T19:15:19Z",
    "timestamp": 1754162119459,
    "version": "3.41.2"
  },
  "reference-count": 55,
  "publisher": "Springer Science and Business Media LLC",
  "issue": "2",
  "license": [
    {
      "start": {
        "date-parts": [
          [
            2001,
            5,
            1
          ]
        ],
        "date-time": "2001-05-01T00:00:00Z",
        "timestamp": 988675200000
      },
      "content-version": "tdm",
      "delay-in-days": 0,
      "URL": "https://www.springernature.com/gp/researchers/text-and-data-mining"
    },
    {
      "start": {
        "date-parts": [
          [
            2001,
            5,
            1
          ]
        ],
        "date-time": "2001-05-01T00:00:00Z",
        "timestamp": 988675200000
      },
      "content-version": "vor",
      "delay-in-days": 0,
      "URL": "https://www.springernature.com/gp/researchers/text-and-data-mining"
    }
  ],
  "content-domain": {
    "domain": [],
    "crossmark-restriction": false
  },
  "published-print": {
    "date-parts": [
      [
        2001,
        5
      ]
    ]
  },
  "DOI": "10.1023/a:1010682916808",
  "type": "journal-article",
  "created": {
    "date-parts": [
      [
        2002,
        12,
        22
      ]
    ],
    "date-time": "2002-12-22T22:31:49Z",
    "timestamp": 1040596309000
  },
  "page": "143-153",
  "source": "Crossref",
  "is-referenced-by-count": 78,
  "title": "Progress in the Development of Alternative Pharmaceutical Formulations of Taxanes",
  "prefix": "10.1007",
  "volume": "19",
  "author": [
    {
      "given": "Bastiaan",
      "family": "Nuijen",
      "sequence": "first",
      "affiliation": []
    },
    {
      "given": "Marjan",
      "family": "Bouma",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "Jan H.M.",
      "family": "Schellens",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "Jos H.",
      "family": "Beijnen",
      "sequence": "additional",
      "affiliation": []
    }
  ],
  "member": "297",
  "reference": [
    {
      "key": "322952_CR1",
      "doi-asserted-by": "crossref",
      "first-page": "381",
      "DOI": "10.3109/07357909509031919",
      "volume": "13",
      "author": "MT Huizing",
      "year": "1995",
      "unstructured": "Huizing MT, Sewberath Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CHN, Vermorken JB, Beijnen JH: Taxanes: a new class of antitumor agents. Cancer Inv 13: 381\u2013404, 1995",
      "journal-title": "Cancer Inv"
    },
    {
      "key": "322952_CR2",
      "doi-asserted-by": "crossref",
      "unstructured": "Straubinger RM: Biopharmaceutics of paclitaxel (Taxol): formulation, activity, and pharmacokinetics. In: Suffness M (ed) Taxolr: Science and Applications. CRC press, 1996, pp 237\u2013258",
      "DOI": "10.1201/9780138737361-12"
    },
    {
      "key": "322952_CR3",
      "first-page": "141",
      "volume": "15",
      "author": "JD Adams",
      "year": "1993",
      "unstructured": "Adams JD, Flora KP, Goldspiel BR, Wilson JW, Arbuck SG, Finley R: Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst 15: 141\u2013147, 1993",
      "journal-title": "J Natl Cancer Inst"
    },
    {
      "key": "322952_CR4",
      "doi-asserted-by": "crossref",
      "first-page": "87",
      "DOI": "10.1016/S0305-7372(97)90022-0",
      "volume": "23",
      "author": "JM Meerum Terwogt",
      "year": "1997",
      "unstructured": "Meerum Terwogt JM, Nuijen B, Ten Bokkel Huinink WW, Beijnen JH: Alternative formulations of paclitaxel. Canc Treat Rev 23: 87\u201395, 1997",
      "journal-title": "Canc Treat Rev"
    },
    {
      "key": "322952_CR5",
      "doi-asserted-by": "crossref",
      "first-page": "418",
      "DOI": "10.2165/00044011-199714050-00011",
      "volume": "14",
      "author": "VR Nannan Panday",
      "year": "1997",
      "unstructured": "Nannan Panday VR, Huizing MT, ten Bokkel Huinink WW, Vermorken JB, Beijnen JH: Hypersensitivity reactions to the taxanes paclitaxel and docetaxel. Clin Drug Invest 14: 418\u2013427, 1997",
      "journal-title": "Clin Drug Invest"
    },
    {
      "key": "322952_CR6",
      "doi-asserted-by": "crossref",
      "first-page": "63",
      "DOI": "10.1007/BF01964882",
      "volume": "7",
      "author": "W Lorenz",
      "year": "1977",
      "unstructured": "Lorenz W, Reimann HJ, Schmal A, Dormann P, Schwarz B, Neugebauer E, Doenicke A: Histamine release in dogs by Cremophor ELr and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 7: 63\u201367, 1977",
      "journal-title": "Agents Actions"
    },
    {
      "key": "322952_CR7",
      "doi-asserted-by": "crossref",
      "first-page": "873",
      "DOI": "10.1177/106002809703100714",
      "volume": "31",
      "author": "DB Wilson",
      "year": "1997",
      "unstructured": "Wilson DB, Beck TM, Gundlach CA: Paclitaxel formulation as a cause of ethanol intoxication. Ann Pharmacother 31: 873\u2013875, 1997",
      "journal-title": "Ann Pharmacother"
    },
    {
      "key": "322952_CR8",
      "first-page": "2112",
      "volume": "56",
      "author": "A Sparreboom",
      "year": "1996",
      "unstructured": "Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JHM: Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Canc Res 56: 2112\u20132115, 1996",
      "journal-title": "Canc Res"
    },
    {
      "key": "322952_CR9",
      "doi-asserted-by": "crossref",
      "first-page": "330",
      "DOI": "10.1038/sj.bjc.6690696",
      "volume": "81",
      "author": "O van Tellingen",
      "year": "1999",
      "unstructured": "van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH: Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 81: 330\u2013335, 1999",
      "journal-title": "Br J Cancer"
    },
    {
      "key": "322952_CR10",
      "doi-asserted-by": "crossref",
      "first-page": "331",
      "DOI": "10.1007/BF00685909",
      "volume": "33",
      "author": "J Liebmann",
      "year": "1994",
      "unstructured": "Liebmann J, Cook J, Lipschultz C: The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines. Cancer Chemother Pharmacol 33: 331\u2013339, 1994",
      "journal-title": "Cancer Chemother Pharmacol"
    },
    {
      "key": "322952_CR11",
      "doi-asserted-by": "crossref",
      "first-page": "133S",
      "DOI": "10.1002/j.1875-9114.1997.tb03815.x",
      "volume": "17",
      "author": "LA Trissel",
      "year": "1997",
      "unstructured": "Trissel LA: Pharmaceutical properties of paclitaxel and their effects on preparation and administration. Pharmacotherapy 17: 133S\u2013139S, 1997",
      "journal-title": "Pharmacotherapy"
    },
    {
      "key": "322952_CR12",
      "doi-asserted-by": "crossref",
      "first-page": "475",
      "DOI": "10.3109/03639049609108353",
      "volume": "22",
      "author": "JD Jonkman-de Vries",
      "year": "1996",
      "unstructured": "Jonkman-de Vries JD, Flora KP, Bult A, Beijnen JH: Pharmaceutical development of (investigational) anticancer agents for parenteral use \u2013 a review. Drug Develop Indust Pharm 22: 475\u2013494, 1996",
      "journal-title": "Drug Develop Indust Pharm"
    },
    {
      "key": "322952_CR13",
      "first-page": "330",
      "volume": "50",
      "author": "S Sweetana",
      "year": "1996",
      "unstructured": "Sweetana S, Akers MJ: Solubility principles and practices for parenteral drug dosage form development. PDA J Pharm Sci Technol 50: 330\u2013342, 1996",
      "journal-title": "PDA J Pharm Sci Technol"
    },
    {
      "key": "322952_CR14",
      "unstructured": "Product information Taxol (Bristol-Myers Squibb, Princeton, US)"
    },
    {
      "key": "322952_CR15",
      "doi-asserted-by": "crossref",
      "first-page": "460",
      "DOI": "10.1021/js960333n",
      "volume": "86",
      "author": "M Ramaswamy",
      "year": "1997",
      "unstructured": "Ramaswamy M, Zhang X, Burt HM, Wasan KM: Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers. J Pharm Sci 86: 460\u2013464, 1997",
      "journal-title": "J Pharm Sci"
    },
    {
      "key": "322952_CR16",
      "doi-asserted-by": "crossref",
      "first-page": "81",
      "DOI": "10.1007/s002800050630",
      "volume": "40",
      "author": "X Zhang",
      "year": "1997",
      "unstructured": "Zhang X, Burt HM, Von Hoff D, Dexter D, Mangold G, Degen D, Oktaba AM, Hunter WL: An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel. Cancer Chemother Pharmacol 40: 81\u201386, 1997",
      "journal-title": "Cancer Chemother Pharmacol"
    },
    {
      "key": "322952_CR17",
      "doi-asserted-by": "crossref",
      "first-page": "696",
      "DOI": "10.1097/00001813-199708000-00008",
      "volume": "8",
      "author": "X Zhang",
      "year": "1997",
      "unstructured": "Zhang X, Burt HM, Mangold G, Dexter D, Von Hoff D, Mayer L, Hunter WL: Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel. Anticancer Drugs 8: 696\u2013701, 1997",
      "journal-title": "Anticancer Drugs"
    },
    {
      "key": "322952_CR18",
      "unstructured": "Product information Taxotere (Rh\u00f4ne-Poulenc Rorer)"
    },
    {
      "key": "322952_CR19",
      "doi-asserted-by": "crossref",
      "first-page": "162",
      "DOI": "10.1023/A:1016483406511",
      "volume": "4",
      "author": "BD Tarr",
      "year": "1987",
      "unstructured": "Tarr BD, Sambandan TG, Yalkowsky SH: A new parenteral emulsion for the administration of Taxol. Pharm Res 4: 162\u2013165, 1987",
      "journal-title": "Pharm Res"
    },
    {
      "key": "322952_CR20",
      "first-page": "170",
      "volume": "52",
      "author": "P Simamora",
      "year": "1998",
      "unstructured": "Simamora P, Dannenfelser RM, Tabibi SE, Yalkowski SH: Emulsion formulations for intavenous administration of paclitaxel. PDA J Pharm Sci Technol 52: 170\u2013172, 1998",
      "journal-title": "PDA J Pharm Sci Technol"
    },
    {
      "key": "322952_CR21",
      "doi-asserted-by": "crossref",
      "first-page": "16",
      "DOI": "10.1111/j.2042-7158.1997.tb06744.x",
      "volume": "49",
      "author": "BB Lundberg",
      "year": "1997",
      "unstructured": "Lundberg BB: A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol). J Pharm Pharmacol 49: 16\u201321, 1997",
      "journal-title": "J Pharm Pharmacol"
    },
    {
      "key": "322952_CR22",
      "doi-asserted-by": "crossref",
      "first-page": "271",
      "DOI": "10.1016/S0168-3659(98)00164-3",
      "volume": "58",
      "author": "P Kan",
      "year": "1999",
      "unstructured": "Kan P, Chen ZB, Lee CJ, Chu IM: Development of nonionic surfactant/phospholipid o/w emulsion as a paclitaxel delivery system. J Controlled Release 58: 271\u2013278, 1999",
      "journal-title": "J Controlled Release"
    },
    {
      "key": "322952_CR23",
      "doi-asserted-by": "crossref",
      "first-page": "191",
      "DOI": "10.3109/02652049009021832",
      "volume": "7",
      "author": "MH Bartoli",
      "year": "1990",
      "unstructured": "Bartoli MH, Boitard M, Fessi H, Beriel H, Devissaguet JP, Picot F, Puisieux F: In vitro and in vivo antitumoral activity of free, and encapsulated taxol. J Microencapsulation 7: 191\u2013197, 1990",
      "journal-title": "J Microencapsulation"
    },
    {
      "key": "322952_CR24",
      "first-page": "281",
      "volume": "8",
      "author": "D Sharma",
      "year": "1996",
      "unstructured": "Sharma D, Chelvi TP, Chakravorty K, De TK, Maitra A, Ralhan R: Novel Taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated Taxol for drug delivery in cancer therapy. Oncol Res 8: 281\u2013286, 1996",
      "journal-title": "Oncol Res"
    },
    {
      "key": "322952_CR25",
      "doi-asserted-by": "crossref",
      "first-page": "279",
      "DOI": "10.1007/BF00689043",
      "volume": "36",
      "author": "SK Dordunoo",
      "year": "1995",
      "unstructured": "Dordunoo SK, Jackson JK, Arsenault LA: Taxol encapsulation in poly(\u2014-caprolactone) microspheres. Cancer Chemother Pharmacol 36: 279\u2013282, 1995",
      "journal-title": "Cancer Chemother Pharmacol"
    },
    {
      "key": "322952_CR26",
      "doi-asserted-by": "crossref",
      "first-page": "73",
      "DOI": "10.1016/0304-3835(94)03614-O",
      "volume": "88",
      "author": "HM Burt",
      "year": "1995",
      "unstructured": "Burt HM, Jackson JK, Bains SK, Liggins RT, Oktaba AM, Arsenault AL, Hunter WL. Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (d,l-lactic acid). Cancer Lett 88: 73\u201379, 1995",
      "journal-title": "Cancer Lett"
    },
    {
      "key": "322952_CR27",
      "first-page": "4242",
      "volume": "5",
      "author": "E Harper",
      "year": "1999",
      "unstructured": "Harper E, Dang W, Lapidus RG, Garver RI: Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER Delivery System) for local-regional therapy of lung cancer tumor nodules in mice. Clin Canc Res 5: 4242\u20134248, 1999",
      "journal-title": "Clin Canc Res"
    },
    {
      "key": "322952_CR28",
      "doi-asserted-by": "crossref",
      "unstructured": "Alkan-Onyuksel H, Ramakrishnan S, Chai HB, Pezzuto JM: A mixed micellar formulation suitable for the parenteral administration of Taxol. Pharm Res 11: 206\u2013212",
      "DOI": "10.1023/A:1018943021705"
    },
    {
      "key": "322952_CR29",
      "first-page": "69",
      "volume": "15",
      "author": "RM Straubinger",
      "year": "1993",
      "unstructured": "Straubinger RM, Sharma A, Murray M, Mayhew E: Novel Taxol formulations: Taxol containing liposomes. J Natl Cancer Inst Mon 15: 69\u201378, 1993",
      "journal-title": "J Natl Cancer Inst Mon"
    },
    {
      "key": "322952_CR30",
      "doi-asserted-by": "crossref",
      "first-page": "889",
      "DOI": "10.1023/A:1018994111594",
      "volume": "11",
      "author": "A Sharma",
      "year": "1994",
      "unstructured": "Sharma A, Straubinger RM: Novel Taxol formulations: preparation and characterization of Taxol-containing liposomes. Pharm Res 11: 889\u2013896, 1994",
      "journal-title": "Pharm Res"
    },
    {
      "key": "322952_CR31",
      "doi-asserted-by": "crossref",
      "first-page": "103",
      "DOI": "10.1002/(SICI)1097-0215(19970328)71:1<103::AID-IJC17>3.0.CO;2-J",
      "volume": "71",
      "author": "A Sharma",
      "year": "1997",
      "unstructured": "Sharma A, Mayhew E, Bolcsak L, Cavanaugh C, Harmon P, Janoff A, Bernacki RJ: Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int J Canc 71: 103\u2013107, 1997",
      "journal-title": "Int J Canc"
    },
    {
      "key": "322952_CR32",
      "doi-asserted-by": "crossref",
      "first-page": "1503",
      "DOI": "10.3109/03639049109026630",
      "volume": "17",
      "author": "O Bekers",
      "year": "1991",
      "unstructured": "Bekers O, Uijtendaal EV, Beijnen JH, Bult A, Underberg WJM: Cyclodextrins in the pharmaceutical field. Drug Dev Ind Pharm 17: 1503\u20131549, 1991",
      "journal-title": "Drug Dev Ind Pharm"
    },
    {
      "key": "322952_CR33",
      "doi-asserted-by": "crossref",
      "first-page": "1017",
      "DOI": "10.1021/js950534b",
      "volume": "85",
      "author": "T Loftsson",
      "year": "1996",
      "unstructured": "Loftsson T, Brewster ME: Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. Pharm Sci 85: 1017\u20131025, 1996",
      "journal-title": "Pharm Sci"
    },
    {
      "key": "322952_CR34",
      "doi-asserted-by": "crossref",
      "first-page": "1223",
      "DOI": "10.1002/jps.2600841015",
      "volume": "84",
      "author": "US Sharma",
      "year": "1995",
      "unstructured": "Sharma US, Balasubramanian SV, Straubinger RM: Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrines. J Pharm Sci 84: 1223\u20131230, 1995",
      "journal-title": "J Pharm Sci"
    },
    {
      "key": "322952_CR35",
      "doi-asserted-by": "crossref",
      "first-page": "329",
      "DOI": "10.1016/0006-291X(84)91557-2",
      "volume": "124",
      "author": "W Mellado",
      "year": "1984",
      "unstructured": "Mellado W, Magri NF, Kingston DGI, Garcia-Arenas R, Orr GA, Horwitz SB: Preparation and biological activity of taxol acetates. Biochem Biophys Res Com 124: 329\u2013336, 1984",
      "journal-title": "Biochem Biophys Res Com"
    },
    {
      "key": "322952_CR36",
      "doi-asserted-by": "crossref",
      "first-page": "1357",
      "DOI": "10.1016/S0960-894X(00)80348-0",
      "volume": "3",
      "author": "DM Vyas",
      "year": "1993",
      "unstructured": "Vyas DM, Wong H, Crosswell AR, Casazza AM, Knipe JO, Mamber SW, Doyle TW: Synthesis and antitumor evaluation of water soluble taxol phosphates. Bioorganic Med Chem Lett 3: 1357\u20131360, 1993",
      "journal-title": "Bioorganic Med Chem Lett"
    },
    {
      "key": "322952_CR37",
      "doi-asserted-by": "crossref",
      "unstructured": "Vyas DM: Paclitaxel (Taxolr) formulation and prodrugs. In: Farina V (ed) The Chemistry and Pharmacology of Taxol and its Derivatives, 103\u2013130, 1995",
      "DOI": "10.1016/S0165-7208(06)80017-6"
    },
    {
      "key": "322952_CR38",
      "doi-asserted-by": "crossref",
      "first-page": "1761",
      "DOI": "10.1016/S0960-894X(00)80058-X",
      "volume": "3",
      "author": "Y Ueda",
      "year": "1993",
      "unstructured": "Ueda Y, Mikkilineni AB, Knipe JO, Rose WC, Casazza AM, Vyas DM: Novel water soluble phosphate prodrugs of Taxolr possessing in vivo antitumor activity. Bioorganic Med Chem Lett 3: 1761\u20131766, 1993",
      "journal-title": "Bioorganic Med Chem Lett"
    },
    {
      "key": "322952_CR39",
      "doi-asserted-by": "crossref",
      "first-page": "1861",
      "DOI": "10.1016/S0960-894X(01)80385-1",
      "volume": "4",
      "author": "Y Ueda",
      "year": "1994",
      "unstructured": "Ueda Y, Wong H, Matiskella JD, Mikkelineni AB, Farina V, Fairchild C, Rose WC, Mamber SW, Long BH, Kerns EH, Casazza AM, Vyas DM: Synthesis and antitumor evaluation of 20-oxycarbonylpaclitaxels (paclitaxel-20-carbonates). Bioorganic Med Chem Lett 4: 1861\u20131864, 1994",
      "journal-title": "Bioorganic Med Chem Lett"
    },
    {
      "key": "322952_CR40",
      "doi-asserted-by": "crossref",
      "first-page": "145",
      "DOI": "10.1021/jm00079a019",
      "volume": "35",
      "author": "AE Mathew",
      "year": "1992",
      "unstructured": "Mathew AE, Mejillano MR, Nath JP, Himes RH, Stella VJ: Synthesis and evaluation of some water-soluble prodrugs and derivatives of Taxol with antitumor activity. J Med Chem 35: 145\u2013151, 1992",
      "journal-title": "J Med Chem"
    },
    {
      "key": "322952_CR41",
      "first-page": "2711",
      "volume": "18",
      "author": "R Paradis",
      "year": "1998",
      "unstructured": "Paradis R, Pag\u00e9 M: New active paclitaxel amino acids derivatives with improved water solubility. Anticancer Res 18: 2711\u20132716, 1998",
      "journal-title": "Anticancer Res"
    },
    {
      "key": "322952_CR42",
      "doi-asserted-by": "crossref",
      "first-page": "464",
      "DOI": "10.1038/364464a0",
      "volume": "364",
      "author": "KC Nicolaou",
      "year": "1993",
      "unstructured": "Nicolaou KC, Riemer C, Kerr MA, Rideout D, Wrasidlo W: Design, synthesis and biological activity of protaxols. Nature 364: 464\u2013466, 1993",
      "journal-title": "Nature"
    },
    {
      "key": "322952_CR43",
      "doi-asserted-by": "crossref",
      "first-page": "2465",
      "DOI": "10.1016/S0960-894X(01)80411-X",
      "volume": "4",
      "author": "RB Greenwald",
      "year": "1994",
      "unstructured": "Greenwald RB, Pendri A, Bolikal D, Gilbert CW: Highly water-soluble taxol derivatives: 20-polyethyleneglycol esters as potential prodrugs. Biorganic Med Chem Lett 4: 2465\u20132470, 1994",
      "journal-title": "Biorganic Med Chem Lett"
    },
    {
      "key": "322952_CR44",
      "doi-asserted-by": "crossref",
      "first-page": "424",
      "DOI": "10.1021/jm950475e",
      "volume": "39",
      "author": "RB Greenwald",
      "year": "1996",
      "unstructured": "Greenwald RB, Gilbert CW, Pendri A, Conover CD, Xia J, Martinez A: Drug delivery systems: water soluble Taxol 20-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J Med Chem 39: 424\u2013431, 1996",
      "journal-title": "J Med Chem"
    },
    {
      "key": "322952_CR45",
      "doi-asserted-by": "crossref",
      "first-page": "642",
      "DOI": "10.1097/00001813-199608000-00004",
      "volume": "7",
      "author": "C Li",
      "year": "1996",
      "unstructured": "Li C, Yu D, Inoue T, Yang DJ, Milas L, Hunter NR, Kim EE, Wallace S: Synthesis and evaluation of water-soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug. Anticancer Drugs 7: 642\u2013648, 1996",
      "journal-title": "Anticancer Drugs"
    },
    {
      "key": "322952_CR46",
      "first-page": "387",
      "volume": "13",
      "author": "A Pendri",
      "year": "1998",
      "unstructured": "Pendri A, Conover CD, Greenwald RB: Antitumor activity of paclitaxel-20-glycinate conjugated to poly(ethylene glycol): a water soluble prodrug. Anticancer Drug Des 13: 387\u2013395, 1998",
      "journal-title": "Anticancer Drug Des"
    },
    {
      "key": "322952_CR47",
      "doi-asserted-by": "crossref",
      "first-page": "293",
      "DOI": "10.1016/S0168-3659(97)01656-8",
      "volume": "47",
      "author": "F Dosio",
      "year": "1997",
      "unstructured": "Dosio F, Brusa P, Crosasso, P, Arpicco S, Cattel L: Preparation and characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate. J Control Rel 47: 293\u2013304, 1997",
      "journal-title": "J Control Rel"
    },
    {
      "key": "322952_CR48",
      "first-page": "307",
      "volume": "36",
      "author": "E Presenti",
      "year": "1995",
      "unstructured": "Presenti E, Franzetti C, Biasoli G: Synthesis and biological activity of water soluble polymer-bound taxol derivatives. Proc Am Ass Cancer Res 36: 307, 1995",
      "journal-title": "Proc Am Ass Cancer Res"
    },
    {
      "key": "322952_CR49",
      "doi-asserted-by": "crossref",
      "first-page": "1408",
      "DOI": "10.1021/jm00036a004",
      "volume": "37",
      "author": "I Ojima",
      "year": "1994",
      "unstructured": "Ojima I, Park YH, Sun CM, Fenoglio I, Appendino G, Pera P, Bernacki RJ: Structure-activity relationships of new taxoids derived from 14\u2014-hydroxy-10-deacetylbaccatin III. J Med Chem 37: 1408\u20131410, 1994",
      "journal-title": "J Med Chem"
    },
    {
      "key": "322952_CR50",
      "doi-asserted-by": "crossref",
      "first-page": "3821",
      "DOI": "10.1021/jm00019a012",
      "volume": "38",
      "author": "SM Ali",
      "year": "1995",
      "unstructured": "Ali SM, Hoemann MZ, Aub\u00e9 J, Mitscher LA, Georg GI: Novel cytotoxic 30-(tert-butyl) 30-diphenyl analogs of paclitaxel and docetaxel. J Med Chem 38: 3821\u20133828, 1995",
      "journal-title": "J Med Chem"
    },
    {
      "key": "322952_CR51",
      "doi-asserted-by": "crossref",
      "first-page": "560",
      "DOI": "10.1038/bjc.1996.98",
      "volume": "73",
      "author": "JD Alder",
      "year": "1996",
      "unstructured": "Alder JD, Jarvis KP, Marsh KC, Klein LL, Clement JJ: Preclinical in vivo efficacy of two 9-dihydrotaxane analogues against human and murine tumors. Br J Cancer 73: 560\u2013564, 1996",
      "journal-title": "Br J Cancer"
    },
    {
      "key": "322952_CR52",
      "doi-asserted-by": "crossref",
      "first-page": "272",
      "DOI": "10.1023/A:1016051316815",
      "volume": "13",
      "author": "E Merisko-Liversidge",
      "year": "1996",
      "unstructured": "Merisko-Liversidge E, Sarpotdar P, Bruno J, Hajj S, Wei L, Peltier N, Rake J, Shaw JM, Pugh S, Polin L, Jones J, Corbett T, Cooper E, Liversidge GG: Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble drugs. Pharm Res 13: 272\u2013278, 1996",
      "journal-title": "Pharm Res"
    },
    {
      "key": "322952_CR53",
      "doi-asserted-by": "crossref",
      "first-page": "368",
      "DOI": "10.1023/A:1016032207246",
      "volume": "13",
      "author": "CI Winternitz",
      "year": "1996",
      "unstructured": "Winternitz CI, Jackson JK, Oktaba AM, Burt HM: Development of a polymeric surgical paste formulation for taxol. Pharm Res 13: 368\u2013375, 1996",
      "journal-title": "Pharm Res"
    },
    {
      "key": "322952_CR54",
      "doi-asserted-by": "crossref",
      "first-page": "717",
      "DOI": "10.1097/00001813-199512000-00002",
      "volume": "6",
      "author": "J Smith",
      "year": "1995",
      "unstructured": "Smith J, Stock E, Orenberg EK, Yu NY, Kanekal S, Brown DM: Intratumoral chemotherapy with sustained-release drug delivery system inhibits growth of human pancreatic cancer xenografts. Anticancer Drugs 6: 717\u2013726, 1995",
      "journal-title": "Anticancer Drugs"
    },
    {
      "key": "322952_CR55",
      "doi-asserted-by": "crossref",
      "first-page": "285",
      "DOI": "10.1016/S0140-6736(98)24030-X",
      "volume": "352",
      "author": "JM Meerum Terwogt",
      "year": "1998",
      "unstructured": "Meerum Terwogt JM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Schellens JHM: Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet 352: 285, 1998",
      "journal-title": "Lancet"
    }
  ],
  "container-title": "Investigational New Drugs",
  "original-title": [],
  "language": "en",
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1023/A:1010682916808.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1023/A:1010682916808/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1023/A:1010682916808.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "deposited": {
    "date-parts": [
      [
        2025,
        7,
        29
      ]
    ],
    "date-time": "2025-07-29T20:01:41Z",
    "timestamp": 1753819301000
  },
  "score": 1,
  "resource": {
    "primary": {
      "URL": "https://link.springer.com/10.1023/A:1010682916808"
    }
  },
  "subtitle": [],
  "short-title": [],
  "issued": {
    "date-parts": [
      [
        2001,
        5
      ]
    ]
  },
  "references-count": 55,
  "journal-issue": {
    "issue": "2",
    "published-print": {
      "date-parts": [
        [
          2001,
          5
        ]
      ]
    }
  },
  "alternative-id": [
    "322952"
  ],
  "URL": "http://dx.doi.org/10.1023/A:1010682916808",
  "relation": {},
  "ISSN": [
    "0167-6997",
    "1573-0646"
  ],
  "subject": [],
  "container-title-short": "Invest New Drugs",
  "published": {
    "date-parts": [
      [
        2001,
        5
      ]
    ]
  }
}